Epithelioid sarcoma as the prototype for personalized therapy in soft tissue sarcoma
Tarek Assi 1 2, Elie Rassy 1, Hussein Nassereddine 1, Fadi Farhat 2, Joseph Kattan 1
Affiliations
1Saint-Joseph University, Faculty of medicine, Beirut, Lebanon.
2Oncology Department, Hammoud Hospital, Saida, Lebanon.
PMID: 32589100
No abstract available
Conclusion
ES is a rare form of STS with a specific molecular alteration on chromosome 22 [SMARCB1/INI1 loss]. Targeting EZH2, as INI1 loss-related affected epigenetic modifier, demonstrated significant activity in ES, a rare tumor with low sensitivity to radiation and chemotherapy. This constitutes a huge leap in the management of STS tumors and should encourage researchers to indulge in the identification of potential targetable oncogenic drivers within each histological subtype.
Keywords: chemotherapy; epithelioid sarcoma; personalized therapy; soft tissue sarcomas; targeted therapy; tazemetostat.
Comments (0)